Two approaches to treating schizophrenia, a severe mental disorder that affects an estimated 1 in 100 adults worldwide, receive contrasting evaluations in new studies.
On the disappointing side, patients with schizophrenia who took any of five highly touted antipsychotic drugs for 1 year experienced only modest gains in holding down jobs, sustaining friendships, and otherwise functioning well in daily life. These drugs, the second generation of such medications, achieved no better results in improving patients’ quality of life than an older antipsychotic medication did.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.